CTIS2023-504827-17-00招募中1 期
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants - CLIN-52120-463
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 1,735
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Participant must be =18 years of age inclusive, at the time of signing the informed consent and privacy/data protection documentation., Participant has a diagnosis for more than 12 months, prior to screening visit, of chronic migraine according to the International Classification of Headache Disorders definition and diagnostic criteria, Migraine onset occurred when participant was <50 years of age., Has baseline number of monthly headache days (MHD) =15 and baseline number of monthly migraine days (MMD) of =8, using eDiary data collected during the 4 weeks nearest to randomisation on Day 1 (but prior to randomisation)., Has baseline number of valid diary days =22 days collected during the 4 weeks nearest to randomisation on Day 1.
排除标准
- •History or current diagnosis of migraine with brainstem aura, retinal migraine, complications of migraine, tension-type headache, trigeminal autonomic cephalalgias, hypnic headache, hemicrania continua, or new daily persistent headache., Headache attributed to another disorder (e.g. secondary headaches), except medication overuse headache, which is permitted., Use of any of the following medications in the specified timeframe prior to start of completion of the screening daily headache eDiary: a. Within 24 weeks i. Botulinum toxin for migraine (or for any other medical/aesthetic reason within 16 weeks) b. Within 12 weeks i. CGRP antagonists (monoclonal antibody or gepant) for preventive treatment of migraine (acute treatment of headache/migraine with a gepant is permitted, but limited to no more than six days per month (i.e. 6 days per each 4-week period with gepant intake)). ii. Cannabidiol or other types of cannabinoids c. Within 4 weeks i. Anaesthetic or steroid injection in any region targeted for injection with study intervention ii. Use of medical device to treat migraine (e.g. non-invasive neuromodulation therapies such as nerve stimulation (gammaCore), transcranial magnetic stimulation (cephaly), external trigeminal nerve stimulation, transcutaneous electrical nerve stimulation, and peripheral neuroelectrical stimulation) iii. Other interventions for migraine assessed to interfere with study evaluations (e.g. acupuncture in head and neck region, cranial traction, nociceptive trigeminal inhibition, occipital nerve block treatments, and dental splints for headache) iv. Use of opioids or barbiturates for more than 2 days/month.
研究者
相似试验
进行中（未招募）
不适用
A Phase III Study of MEDI4736 as Sequential Therapy in Patients with Locally Advanced Non-Small Cell Lung CancerEUCTR2014-000336-42-ESAstraZeneca AB880
进行中（未招募）
1 期
A Phase III Study of MEDI4736 as Sequential Therapy in Patients with Locally Advanced Non-Small Cell Lung Cancerocally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III)MedDRA version: 21.1 Level: LLT Classification code 10066490 Term: Progression of non-small cell lung cancer System Organ Class: 100000004864MedDRA version: 21.1 Level: LLT Classification code 10029514 Term: Non-small cell lung cancer NOS System Organ Class: 100000004864EUCTR2014-000336-42-GBAstraZeneca AB1,000
进行中（未招募）
不适用
A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 10 mg ZD4054 in Combination with Docetaxel in Comparison with Docetaxel in Patients with Metastatic Hormone-resistant Prostate Cancerhormone-resistant prostate cancerEUCTR2007-003228-39-PTAstraZeneca AB1,048
进行中（未招募）
1 期
A Phase III Study of MEDI4736 as Sequential Therapy in Patients with Locally Advanced Non-Small Cell Lung Cancerocally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III)MedDRA version: 17.0Level: LLTClassification code 10066490Term: Progression of non-small cell lung cancerSystem Organ Class: 100000004864MedDRA version: 17.0Level: LLTClassification code 10029514Term: Non-small cell lung cancer NOSSystem Organ Class: 100000004864EUCTR2014-000336-42-ITAstraZeneca AB880
进行中（未招募）
1 期
A Phase III Study of MEDI4736 as Sequential Therapy in Patients with Locally Advanced Non-Small Cell Lung Cancerocally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III)MedDRA version: 20.0Level: PTClassification code 10029519Term: Non-small cell lung cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-000336-42-PLAstraZeneca AB713